Treatment of hallucinations and delusions in Parkinson disease

Abstract

Parkinson disease psychosis (PDP) is a common and significant behavioral problem associated with increased mortality and morbidity in patients. It is no longer thought to arise solely as a side effect to dopaminergic medications, but from a complex interplay of extrinsic and intrinsic factors. Management of PDP involves a search for medical causes of delirium, a thorough review of medications, and initiation of a psychopharmacologic treatment such as clozapine, quetiapine, or newly approved pimavanserin, if needed.